Results 1 to 10 of about 6,952 (109)

Trends in the Dispensing of Oral Anti-Cancer Medications Across Australia Over 10 Years. [PDF]

open access: yesPharmacoepidemiol Drug Saf
ABSTRACT Purpose Oral anti‐cancer medications (OAMs) are easily administered yet high‐risk treatments. Few studies have investigated national and subnational trends in OAM dispensing. We aimed to examine 10‐year trends in Australia's OAM dispensing at the national level as well as by state/territory and medication type/class.
Leach MJ   +5 more
europepmc   +2 more sources

SGLT2i and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction in Patients With Diabetes. [PDF]

open access: yesJACC CardioOncol
BACKGROUND: Specific cancer treatments can lead to cancer therapy-related cardiac dysfunction (CTRCD). Sodium glucose cotransporter-2 inhibitors (SGLT2is) can potentially prevent these cardiotoxic effects.
Bhatti AW   +24 more
europepmc   +3 more sources

Association Between Treatment of Childhood Cancer and Its Late Effects on Gonadal or Growth Function in Childhood Cancer Survivors: A Retrospective Observational Study. [PDF]

open access: yesCancer Med
ABSTRACT Background The late effects on childhood cancer survivors have long been recognized, but detailed studies remain limited. The current study aimed to clarify the association between childhood cancer treatment and the incidence of late effects on gonadal or growth function in Japan.
Urakawa R   +5 more
europepmc   +2 more sources

INNs granted with specific storage requirements in Bulgarian pharmacies. Part 2: Antineoplastic and immunomodulating agents [PDF]

open access: yes, 2023
There are drugs that require special storage in Bulgarian pharmacies as well as extra caution during the dispensing process. This is due to serious adverse reactions that may be even fatal. These medicines are included in Appendix № 9 to Art. 17, para. 1
Georgiev, Kaloyan D.   +2 more
core   +2 more sources

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Understanding the different mechanisms of cardiovascular toxicity [PDF]

open access: yes, 2022
Copyright © 2022 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.Due to the success of finding treatments for various types of cancer, overall cancer survival has increased substantially in recent decades ...
Toste, Júlia Cristina
core   +1 more source

Pregnancy-associated breast cancer - Special features in diagnosis and treatment [PDF]

open access: yes, 2006
For obvious psychological reasons it is difficult to associate pregnancy - a life-giving period of our existence with life-threatening malignancies. Symptoms pointing to malignancy are often ignored by both patients and physicians, and this, together ...
Bauerfeind, I.   +7 more
core   +1 more source

Predicting venous thromboembolism (VTE) risk in cancer patients using machine learning [PDF]

open access: yes, 2023
Background: The association between cancer and venous thromboembolism (VTE) is well-established with cancer patients accounting for approximately 20% of all VTE incidents.
Basu, Debraj   +5 more
core   +1 more source

5-Azacytidine and 5-aza-2'-deoxycytidine behave as different antineoplastic agents in B16 melanoma. [PDF]

open access: yes, 1987
The antiproliferative effects of 5-azacytidine (acaCyd) and 5-aza-2'-deoxycytidine (azadCyd) were studied in murine B16 melanoma and a series of B16 melanoma derived mutant strains with selective resistances to the respective drugs.
Bernheim, J.   +3 more
core   +2 more sources

Synthesis and anticancer activity of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives [PDF]

open access: yes, 2016
The development of new antitumor agents is one of the most pressing research areas in medicinal chemistry and medicine. The importance of triazole and thiadiazole rings as scaffolds present in a wide range of therapeutic agents has been well reported and
Camoutsis, Charalambos   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy